Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 02 2024
0mins
Source: Newsfilter
Company Name Change: Eliem Therapeutics, Inc. has rebranded to Climb Bio, Inc., reflecting its new focus on developing treatments for immune-mediated diseases following the acquisition of Tenet Medicines, Inc. The company will trade under the ticker symbol "CLYM" starting October 3, 2024.
Lead Product Candidate: Climb Bio's lead product, budoprutug, is an anti-CD19 monoclonal antibody that aims to treat various B-cell mediated diseases and has shown promising results in early clinical trials, particularly in patients with membranous nephropathy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
